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Introduction
Genes coding for δ, κ and µ opioid receptor types have been identified and isolated from different vertebrates and belong to the G protein-coupled receptor (GPCR) superfamily. The opioid receptors and endogenous opioid peptides form a neuromodulatory system that plays a major role in the control of nociceptive pathways.
The opioid system also modulates affective behavior, neuroendocrine physiology, and controls autonomic functions such as respiration, blood pressure, thermoregulation and gastrointestinal motility. Importantly the receptors are targets for exogenous narcotic opiate alkaloids that constitute a major class of drugs of abuse (Massotte and Kieffer, 1998 ) (Bodnar and Hadjimarkou, 2003) .
GPCR signaling is a complex process whose modulation likely proceeds from many intricate factors. Recently, a possible involvement of the receptor oligomerization state has received growing attention since existence of homo-and hetero-dimers has been postulated for an increasing number of GPCRs (recently reviewed in (Milligan, 2004; Park et al., 2004; Prinster et al., 2005) . Arguments in favor of a spatial proximity between receptor molecules mainly arose from co-immunoprecipitation studies and more recently from bioluminescence and fluorescence resonance energy transfer experiments (recently reviewed in (Milligan and Bouvier, 2005) . However establishing physical proximity between receptors does not necessarily imply functional interactions between them. Even when modifications of the signaling properties appeared correlated with receptor co-localization, the underlying mechanisms remained largely unknown (Gomes et al., 2004) .
Heterodimerization between mu and delta opioid receptor types has already been reported (George et al., 2000; Gomes et al., 2000) and appears of particular interest This article has not been copyedited and formatted. The final version may differ from this version.
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jpet.aspetjournals.org Downloaded from because it may modulate opioid analgesia (Gomes et al., 2004) . In this context, receptor-G protein fusions may help to elucidate the molecular interactions taking place when the two receptor types are co-expressed. Mu and delta opioid receptors have previously been fused to a pertussis toxin insensitive mutant Gα subunit from the inhibitory G i/o family. As a result, signaling through the fusion can be isolated from the cellular background and the extent of activation of the mutant Gα measured in pertussis toxin treated cells (Moon et al., 2001; Massotte et al., 2002) .
In this work, we compared ligand binding properties and activation profiles of the pertussis toxin insensitive G i1 α subunit when mu or delta opioid receptor-Gα fusions are expressed alone or co-expressed with wild-type delta or mu opioid receptors respectively. Our data indicate that heterodimers are formed between mu and delta opioid receptors that retain their structural integrity. These mu-delta heterodimers appear to signal through a mechanism that involves a direct interaction between the non-fused receptor and the Gα subunit.
al., 2002) and maintained in the presence of 100 µg/mL geneticin. Upon co-expression of the receptors, cells were transfected with Jet-PEI reagent according to the manufacturer's recommendations and collected after 48 hours. Pertussis toxin (PTX) treatment was performed for 20 h at a concentration of 100 ng/mL before cells were harvested.
Preparation of membranes
Cells were collected, washed twice with PBS and stored at -80°C in PBS containing 320 mM sucrose. Cell pellets were resuspended in ice-cold 50 mM Tris-HCl, 1 mM EDTA, pH 7.4, disrupted using a glass homogenizer and centrifuged at 2000 g for 10 min. The pellet was homogenized in ice-cold 50 mM Tris-HCl, 1 mM EDTA, pH 7.4 and centrifuged at 1000 g for 5 min. Both supernatants were combined and ultracentrifuged at 100 000 g for 40 min at 4°C. The pellet was resuspended in 50 mM Tris-HCl, 1mM
EDTA, 320 mM sucrose, pH 7.4 then homogenized through a 26-gauge needle and stored in aliquots at -80°C before use.
Saturation and competition analysis
For each assay, 10 µg of membrane protein was incubated in 50 mM pH 7.4 with the appropriate ligands in a final volume of 500 µl for 30 min at 22°C. 
Co-immunoprecipitation and Western Blot analysis
Membrane preparations (500 µg) were solubilized in Tris-HCl 50 mM pH 7.4, 100 mM NaCl, 10% CHAPS, complete protease inhibitor cocktail (Roche applied Bioscience, This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Co-immunoprecipitation
Co-immunoprecipitation has been previously used to demonstrate physical proximity between co-expressed mu and delta opioid receptors and hence to establish the existence of heterodimers (George et al., 2000; Gomes et al., 2000) . Coimmunoprecipitation experiments were then performed to confirm mu-delta physical proximity under our conditions.
Membranes from cells co-expressing the delta opioid receptor fused to a pertussis toxin insensitive Gα protein (hDOR-C351I G i1 α with a FLAG-tagged mu opioid receptor (FLAG-MOR) or membranes from cells co-expressing the mu opioid receptor fused to a pertussis toxin insensitive Gα protein (hMOR-C351I G i1 α) with a FLAG-tagged delta opioid receptor (FLAG-DOR) were subjected to coimmunoprecipitation with a polyclonal anti-FLAG antibody. In both cases, detection Similar opioid receptor dimers were detected earlier following immunoprecipitation on solubilized membranes co-expressing mu and delta opioid receptors (George et al., 2000; Gomes et al., 2000) . Also dimers were observed when delta opioid receptors were co-expressed with kappa opioid or β2-adrenergic receptors (Jordan and Devi, 1999; McVey et al., 2001) or when mu opioid receptors were expressed with α 2A -adrenergic, sst2 somatostatin or neurokinin NK1 receptors (Pfeiffer et al., 2002; Jordan et al., 2003; Pfeiffer et al., 2003) .
We verified the specificity of the mu-delta interaction by control experiments that included immunoprecipitation assays from membranes expressing either the receptor-G protein fusion alone, the non-fused FLAG-tagged receptor alone or a mixture of membranes expressing either the receptor-G protein fusion or the non-fused FLAG-tagged receptor alone. For these latter samples, PVDF membranes were stripped and reprobed with the monoclonal M2 anti-FLAG antibody to verify immunoprecipitation efficiency (data not shown).
Effect of receptor co-expression on high affinity ligand binding sites
Co-expression of mu and delta opioid receptors was achieved by transfecting one type of receptor in cells stably expressing the other type. One receptor type was expressed as a receptor-Gα fusion together with a non-fused receptor molecule of the other type. In most experiments, the molar ratio between fused and non-fused receptors was of 1:1 but modifying this ratio to 2:1 in favor of any of the partners had no noticeable effect. In order to avoid possible cross-reactivity when the two opioid This article has not been copyedited and formatted. The final version may differ from this version. receptor types were co-expressed, we chose ligands with nanomolar affinities and high selectivity for either delta or mu opioid receptors.
The agonist DAMGO showed similar nanomolar affinity values and high selectivity for the fused (hMOR-C351I G i1 α) and wild-type (hMOR) mu opioid receptors under our conditions (Table 1) . Likewise the agonists deltorphin II and SNC 80 exhibited nanomolar affinities and high selectivity for the delta receptor in fusion (hDOR-C351I G i1 α) or not (hDOR) ( Table 1 ). Co-expression of hMOR-C351I G i1 α together with hDOR or co-expression of hDOR-C351I G i1 α together with hMOR did not significantly modify high affinity Ki values for all ligands tested. These data suggest that the integrity of the binding sites was not altered upon receptor co-expression.
Effect of co-expression on agonist-induced activation of the receptor-Gα fusion
Incorporation of the non-hydrolysable GTP-analogue [ (Figure 2a ). It should be noted that G protein activation was similar whether hMOR-C351I G i1 α was stably or transiently expressed (data not shown).
Dose-response curves using DAMGO indicated that hMOR-C351I G i1 α maximal activation was reduced to approximately half in the presence of hDOR ( Figure   3a , Table 2 ). Interestingly co-expression induced a decrease in activation of the fused Gα without affecting EC 50 values which suggests that co-expression does not affect the structural integrity of the receptors (Table 2 ).
Similarly [ 35 S]GTPγS incorporation following addition of delta agonists was
significantly reduced in the hDOR-C351I G i1 α fusion upon hMOR co-expression.
Addition of 100 nM deltorphin II led to only 199±16% activation over basal compared to 333±22% when the fusion was expressed alone (p<0.001) (Figure 2b ). Stimulation by 10 nM SNC 80 resulted in 168±9% activation compared to 291±18% when the fusion was expressed alone (p<0.001). Dose-response curves using SNC 80 also indicated a marked reduction of the maximal activation when hMOR was co-expressed with hDOR-C351I G i1 α ( Figure 3b , Table 2 ). As observed in the case of hMOR-C351I G i1 α,
EC 50 values remained unchanged upon co-expression suggesting once more that coexpression does not affect the structural integrity of the receptors (Table 2) .
Expression levels for all constructs were typically 1-3 pmol/mg of membrane protein and did not significantly vary upon co-expression. Also we verified that receptor expression levels and G protein activation were both similar whether cells stably expressing one receptor type were mock transfected or not (data not shown). Therefore
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Gα subunit activation by non-fused co-expressed receptors
We next examined whether the Gα subunit could be activated by co-expressed non-fused receptors. We then tested whether blocking the receptor of the receptor-Gα fusion would prevent G protein activation by the non-fused receptor. CTAP has been previously described as a mu opioid receptor antagonist (Sterious and Walker, 2003) . When hMOR-C351I G i1 α was co-expressed together with hDOR, 100 nM CTAP did not activate the Gα protein fused to the mu opioid receptor (101±4%) and was able to efficiently antagonize 100 nM DAMGO activation (107±6% versus 185±16%, p<0.01) (Figure 5a ). However 100 nM CTAP could not block [ 35 S]GTPγS incorporation into the Gα subunit promoted by the delta agonists deltorphin II (143±5% versus 132±5% for 100 nM deltorphin II alone) or SNC 80 (133±10% versus 131±7% for 10 nM SNC 80 alone) (Figure 5a ).
Tic-deltorphin is a synthetic peptide with antagonistic properties and high delta opioid receptor selectivity (Schiller et al., 1999) . When hDOR-C351I G i1 α was coexpressed with hMOR, 100 nM Tic-deltorphin promoted no Gα activation (98±4%) and was able to efficiently antagonize [ (Figure 5b ). However Tic-deltorphin did not antagonize activation of the Gα protein by 100 nM DAMGO (134±8% compared with 132±3% for DAMGO alone) (Figure 5b ). These data suggest that antagonists for the fused receptor have no effect on Gα subunit activation by the non-fused receptor.
This article has not been copyedited and formatted. The final version may differ from this version. Antagonists bind with similar affinity to both active and inactive forms of receptors while inverse agonists are thought to favor inactive conformations (Strange, 2002) . Recently N,N(CH3) 2 -Dmt-Tic-NH 2 has been characterized as an inverse agonist with nanomolar affinity for the delta opioid receptor (Tryoen-Toth et al., 2005) .
Similarly to the antagonist Tic-deltorphin, N,N(CH3) 2 -Dmt-Tic-NH 2 was able to efficiently reverse [ 
Discussion
An increasing number of GPCRs have been reported to form heterodimers with altered signaling and trafficking properties (Park et al., 2004) . In this context mu and delta opioid receptors appear of particular interest since heterodimers formed between these two receptors may modulate the response to opioids (Gomes et al., 2004 ).
Therefore we investigated the molecular interactions that lead to the activation of the first step of the signaling cascade when the two receptors are co-expressed. did not alter mu opioid receptor trafficking making unlikely a chimeric heterodimer (Law et al., 2005 ).
An interaction without domain exchange is supported by the rhodopsin organization. Atomic force microscopy revealed an oligomeric organization for rhodopsin in native membranes that corresponds to rows of dimers (Fotiadis et al., 2003; Liang et al., 2003) . Within the rhodopsin dimer transmembrane domains TM 4
and 5 appear to form the strongest interface of interaction between monomers while contact sites between adjacent dimers would take place between TM 1 and 2 and intracellular loop 3 (Fotiadis et al., 2003; Liang et al., 2003) . Importantly modeling studies have also highlighted TM 4 and 5 as the most likely interface for delta opioid homodimers (Filizola and Weinstein, 2002) .
In this context we tried to establish the functional impact of heterodimerization and to determine the molecular interactions that take place between the active receptor and the G protein.
When an agonist specific for the non-fused receptor was added, significant activation of the Gα subunit in fusion was observed. Interestingly results obtained using co-expression of hMOR with the delta opioid receptor-Gα fusion were the mirror image of those obtained when hDOR was co-expressed with the mu opioid receptor-Gα fusion (Figure 4 ). This suggests that the non-fused receptor is able to promote activation of the Gα subunit tethered to the other receptor. Using a similar paradigm, Molinari et al. also detected G protein activation when a non-functional fusion between the delta opioid receptor and a G s α subunit was co-expressed with a non-fused β 2 -adrenergic receptor (Molinari et al., 2003) . Inverse agonists stabilize the receptor in an inactive state (Strange, 2002) . Very few inverse agonists have been described for the opioid receptors. Among them, ICI 174864 serves as a reference but has a low affinity for the delta opioid receptor (Costa and Herz, 1989) . Recently N,N(CH3) 2 -Dmt-Tic-NH 2 was identified as another potent delta specific inverse agonist with nanomolar affinity (Tryoen-Toth et al., 2005) . Under our conditions, N,N(CH3) 2 -Dmt-Tic-NH 2 efficiently reversed delta agonist induced G protein activation through the receptor in fusion as expected (Figure 5b ). On the other hand, it had no effect on activation by the non-fused receptor as also observed with neutral antagonists (Figure 5 ). These data support again a model in which the 19 amino acid linker of the fusion protein is indeed long enough to allow the Gα subunit some degree of motion resulting in Gα subunit interaction by the non-fused receptor (Figure 6 configuration II).
An alternative mechanism can also be postulated by which activation of the nonfused receptor induces a conformational change that is transmitted from the active receptor to the Gα subunit located in trans via the transmembrane domains of the receptor in fusion (Figure 6 configuration I ). In such a configuration decreased Gα activation of the fusion construct would also be observed upon co-expression with a non-fused receptor. However this model is not supported by inverse agonist data ( Figure   5 ). According to such an allosteric mechanism, G protein activation should then be prevented by an inverse agonist of the fused receptor that would constrain it in an inactive state.
Similarly, no G protein activation would be observed if the Gα subunit from the fusion construct was physically interacting with the non-fused receptor and G protein activation would occur via an allosteric process. In this case, the conformational change resulting from the activation of the non-fused receptor would be transferred to a neighbor uncoupled receptor (Figure 6 configuration III).
In summary, we propose that co-expressed mu and delta opioid receptors are a, DAMGO at hMOR-C351I G i1 α expressed alone (■) or together with hDOR (◆).
hMOR-C351I G i1 α was stably expressed and hDOR was transiently expressed.
Expression levels were respectively 1.1 and 1.4 pmol/mg for hMOR-C351I G i1 α expressed alone or together with hDOR and 2.4 pmol/mg for hDOR.
This article has not been copyedited and formatted. The final version may differ from this version. b, SNC 80 at hDOR-C351I G i1 α expressed alone (▲) or together with hMOR(▼).
hDOR-C351I G i1 α was transiently expressed and hMOR was stably expressed.
Expression levels were respectively 1.2 and 1.7 pmol/mg for hDOR-C351I G i1 α expressed alone or together with hMOR and 1.8 pmol/mg for hMOR.
Cells were treated with 100 ng/ml pertussis toxin for 20 h. Data are represented as mean from one representative experiment. A schematic representation of the receptor pairs used in the experiment is represented above each panel. Table 1 Binding affinities for hDOR and hMOR expressed in HEK 293 cells alone or together with the fusion constructs to the pertussis insensitive C351I G i1 α subunit (hDOR/G i1 α and hMOR/G i1 α respectively). Competition experiments were as described in the Materials and Methods. Data are given as a mean ± SEM from at least 3 independent experiments performed in duplicate. Nd :not determined 
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